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Background: Direct oral anticoagulants that target a single coagulation factor have been developed as an
alternative to standard therapies with heparin and/or vitamin K antagonists. The purpose of this study was to derive
non-inferiority margins suitable for randomised clinical studies designed to evaluate these agents for the treatment
of venous thromboembolism (VTE).
Methods: We performed a systematic review to derive non-inferiority margins suitable for use in studies evaluating
direct oral anticoagulants for the treatment of VTE. A PubMed search identified publications that evaluated current
standard treatment versus placebo, ‘no treatment’ or ‘less intensive treatment’ in patients with symptomatic deep
vein thrombosis (DVT) and/or pulmonary embolism (PE). Publications were eligible if they had a randomised study
design, included patients with symptomatic DVT and/or PE, used objective diagnostic methods to document the
index event and reported objectively confirmed symptomatic recurrent VTE.
Results: Fourteen publications were included in the analysis. Recurrent VTE occurred in 25 (1.5%) out of 1715 patients
who received current standard of care and in 157 (9.2%) out of 1711 patients who received placebo, ‘no treatment’ or
‘less intensive treatment’, for an odds ratio of 0.18 (95% confidence interval, 0.14−0.25; test for heterogeneity, p=0.87).
In order to preserve 50% or 75% of the established treatment effect using a linear scale, the corresponding thresholds
for non-inferiority equalled 2.50 and 1.75, respectively.
Conclusions: This systematic review and statistical approach determined non-inferiority margins suitable for use in
studies of direct oral anticoagulants for the treatment of DVT and/or PE.
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Adjusted-dose unfractionated heparin or bodyweight-
adjusted low molecular weight heparin overlapping with
and followed by laboratory-titrated vitamin K antagonists
(VKAs) is widely accepted as the standard treatment for
patients presenting with acute deep vein thrombosis
(DVT) and/or pulmonary embolism (PE) [1]. Although
highly efficacious and relatively safe, this treatment regi-
men is associated with a considerable number of disad-
vantages, including the need for parenteral administration
of heparin and frequent laboratory monitoring of the* Correspondence: mh.prins@maastrichtuniversity.nl
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distribution, and reproduction in any mediumpharmacodynamic effects of VKAs with subsequent dose
adjustments.
Recently, small molecules have been developed that
directly inhibit a single component of the coagulation
cascade (such as Factor Xa or thrombin), can be taken
orally and have a predictable pharmacokinetic/pharma-
codynamic profile [2-4]. Although this eliminates the
need for parenteral administration and routine coagula-
tion monitoring, it is essential that these new compounds
are demonstrated to be clinically as efficacious as the
current standard treatment. Demonstration of similar effi-
cacy requires randomised trials involving patients with
symptomatic DVT and/or PE that compare the incidences
of recurrent venous thromboembolism (VTE) between
the new compounds and the current standard treatment.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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the direct oral anticoagulants need to satisfy a non-
inferiority margin that is based on the documented
efficacy of current standard treatments [5,6].
In this paper, we systematically reviewed all studies
that have evaluated the efficacy of the current standard
treatment for DVT and/or PE and calculated accom-
panying non-inferiority margins from the meta-analysis.
Methods
Literature search
A PubMed search was undertaken for articles reporting
the results of controlled randomised trials between the
dates of 1959 and 2013 to identify studies that compared
the currently recommended anticoagulant treatment ap-
proach with placebo, ‘no treatment’ or a ‘less intensive’
heparin/VKA regimen. The search relied on titles, ab-
stracts and multiple database descriptors and was not re-
stricted by language. The following key words were used
to identify potential relevant publications and eligible stud-
ies for inclusion from a search of MEDLINE: heparin or
low molecular weight heparin, venous thrombo*, vitamin
K antagonist, warfarin, acenocoumarol, phenprocoumon
and fluindione, and the publications were limited to
randomised controlled trials. This broad search approach
was followed by an extensive manual search. Reports were
eligible if they included a randomised study design, in-
cluded patients with symptomatic DVT and/or PE, used
objective diagnostic methods to document the index
event and reported objectively confirmed symptomatic
recurrent VTE. The early study of Barritt and Jordan in
1960 is, in fact, the only ‘no-treatment controlled’ study
and treated patients for 14 days only [7]. Other early
studies dated between 1979 and 1993 addressed mainly
the initial 3 months of treatment and used ‘less intensive’
heparin therapy and/or VKA treatment [8-13]. Studies
published since 1993 addressed mainly the need for con-
tinuation of VKA therapy and compared this therapy to
‘no treatment’ or placebo treatment in the initial 4 weeks
to 6 months after the index event [14-20]. All studies in-
volving ‘less intensive’ regimens that were demonstrated
to be superior versus placebo or ‘no treatment’ were
excluded.Data extraction
The authors independently extracted the following data
from each of the eligible publications: presentation with
DVT and/or PE, treatment characteristics, number of
patients per group and incidence of recurrent fatal/
non-fatal VTE per group during the period of compari-
son between placebo, ‘no treatment’ or ‘less intensive
treatment’. Differences in opinion or interpretation
were resolved by consensus.Statistical analysis
The incidences of recurrent VTE for the different treat-
ment arms were used to calculate a separate odds ratio
for each trial. These odds ratios were then combined
across studies, giving weight to the number of events in
each of the two treatment groups in each separate study,
using the Mantel–Haenszel procedure [21], which as-
sumes a fixed treatment effect. In addition, risk ratios
were calculated using the metafor package in ‘R’. Like-
wise, 95% confidence intervals (CIs) for the effect esti-
mate were calculated, and heterogeneity was statistically
assessed. From the observed efficacy estimates and the
lower limits of the CIs, thresholds were calculated for
the retention of 50%, 66% and 75% of the treatment
effect on both arithmetic and geometric scales.Results
A total of 5388 publications were identified in our litera-
ture search, which used the seminal publication of Barritt
and Jordan as a starting point [7]. Review of the identified
publications in accordance with the eligibility criteria
resulted in the selection of a further 14 studies. One study
was excluded because the ‘less intensive treatment’ regi-
men had been shown to be superior to placebo in another
study [22,23]. Of the 14 studies included, nine evaluated
anticoagulant therapy for a duration of up to 3 months
[7-15], three for a duration of up to 12 months, [16,17,19]
and two for longer durations [18,20].
Current standard of care was compared with placebo in
five studies, with ‘no treatment’ in three studies and with
‘less intensive treatment’ in six studies. The design char-
acteristics of these studies are summarised in Table 1.
The results per study are summarised in Table 2.Establishing the non-inferiority margin
Recurrent VTE occurred in 25 (1.5%) of 1715 patients
who received current standard of care and in 157 (9.2%) of
1711 patients who received placebo, ‘no treatment’ or ‘less
intensive treatment’ (Table 2). Therefore, the observed
treatment effect for prevention of recurrent VTE was
associated with an odds ratio of 0.18 (95% CI 0.14−0.25;
test for heterogeneity, p=0.87) and a risk ratio of 0.19
(95% CI 0.12−0.28; test for heterogeneity, p=0.85).
Conversely, in the absence of current standard treat-
ment, the risk of recurrent VTE increased with an odds
ratio of 5.56 (95% CI 4.00−7.14) or a risk ratio of 5.26
(95% CI 3.57−8.33) (Table 3). Hence, the lower limits of
the 95% CIs of the effect needed to be maintained rele-
vant for the calculation of the non-inferiority thresholds
were 4.00 for the odds ratio and 3.57 for the risk ratio
(Table 3). Thus, to preserve 50% of the established treat-
ment effect, the threshold for non-inferiority equalled
2.50 if calculated using an odds ratio and 2.29 if
Table 1 Summary of design characteristics for the 14 selected studies
Study Patient
population





Barritt [7] PE Intravenous UFH q6h
vs placebo
VKA. PT 2.0–3.0 times control
vs placebo
14 days 3 months
Hull [8] DVT Intravenous UFH VKA started on day 10, PT 1.5–
2.0 vs subcutaneous UFH bid
6 weeks for calf DVT and




DVT UFH VKA started on day 1,
TT 5–14%





Intravenous UFH VKA started on day 1,
INR 2.5–4.2 vs placebo





VKA started on day 6 or 7,
INR 2.0–3.0





Intravenous UFH vs placebo VKA started on day 1,
INR 2.0–3.0
6 months 3 months
Raschke
[13]
DVT or PE Intravenous weight-based UFH vs
‘standard care’ UFH nomogram





Intravenous UFH VKA INR 2.0–3.0 vs placebo 4 weeks vs 12 weeks 3 months
Schulman
[15]
DVT or PE Intravenous UFH or
subcutaneous LMWH
VKA started on day 1,
INR 2.00–2.85















PE Intravenous UFH or
subcutaneous LMWH
















DVT or PE Intravenous UFH or
subcutaneous LMWH










VKA INR 2.00–2.85 vs
no treatment
Indefinitely vs none Month 6 onwards
bid: twice daily; DVT: deep vein thrombosis; INR: international normalised ratio; PE: pulmonary embolism; PT: prothrombin time; q6h: every 6 hours; TT: thrombin
time; UFH: unfractionated heparin; VKA: vitamin K antagonist; VTE: venous thromboembolism.
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preserve 75% of the treatment effect, these thresholds
should be 1.75 and 1.64, respectively (Table 3). In Table 3,
the limits on a geometric scale are also presented.
The point estimates of the relative treatment effects be-
tween studies with a treatment duration of 3 months and
studies with a treatment duration of longer than 3 months
were consistent with odds ratios of 0.18 (95% CI 0.11−0.32)
and of 0.18 (95% CI 0.12−0.28), respectively.Discussion
Our systematic review of the medical literature demon-
strates that the current standard treatment for VTE is
highly efficacious, with a pooled odds ratio of 0.18 and a
pooled risk ratio of 0.19, corresponding to a relative risk
reduction of over 80%. Based on this review, non-
inferiority margins of 2.50, 2.00 and 1.75 could be calcu-
lated using odd ratios, corresponding to maintenance ofdocumented efficacy of current standard treatment of
50%, 66% and 75%, respectively, on a linear scale. In
general, if the non-inferiority margins were based on a
risk ratio, the margins would be lower than that based
on the odds ratio, which would lead to somewhat larger
sample sizes.
The meta-analysis on which these margins are based
included a large variety of studies undertaken over a
long time period (i.e. between 1960 and 2013). Our
search yielded more than 5000 potential references for
review. However, attempts to narrow the search resulted
in the loss of pertinent articles known to the authors.
Even using these broad search criteria, the pertinent ref-
erence of Barritt and Jordan was not found. Therefore,
the approach was supplemented by an extensive manual
search to identify all relevant studies. All 14 included
studies had a randomised design, reported clinical out-
comes and documented the incidence of recurrent VTE.
Although all studies included a group of patients that
Table 2 Recurrent venous thromboembolic events during
the comparison period
Study Current standard
of care, n/N (%)
Placebo, ‘no treatment’ or
‘less intensive treatment’,
n/N (%)
Barritt [7]* 0/16 (0.0) 11/19 (57.9)
Hull [8]† 0/33 (0.0) 6/35 (17.1)
Holmgren [9]‡ 3/66 (4.5) 6/69 (8.7)
Lagerstedt [10]† 0/23 (0.0) 7/28 (25.0)
Hull [11] 3/58 (5.2) 11/57 (19.3)
Brandjes [12]§ 2/60 (3.3) 10/60 (16.7)
Raschke [13] 2/41 (4.9) 8/32 (25.0)
Levine [14] 1/109 (0.9) 9/105 (8.6)
Schulman [15]¶ 4/454 (0.9) 26/443 (5.9)
Agnelli [16]** 4/134 (3.0) 11/133 (8.3)
Agnelli [17]†† 1/165 (0.6) 6/161 (3.7)
Kearon [18] 1/79 (1.3) 17/83 (20.5)
Pinede [19]‡‡ 1/361 (0.3) 6/375 (1.6)




25/1715 (1.5) 157/1711 (9.2)
*This includes one event in the no treatment group at 8 weeks. †Only symptomatic
recurrent events were considered. ‡Based on figure one of the publication. When
one treatment arm was shorter than 3 months, then only events that accumulated
up to 3 months were counted. §Events after 3 months were excluded. ¶Data
provided by author. **Only events between 3 and 12 months were included.
††Only events between 3 and 12 months were included for patients with idiopathic
PE and between 3 and 6 months for patients with provoked PE. ‡‡Only events
between weeks 6 and 12 for patients with isolated calf DVT and between 3 and 6
months for patients with proximal DVT and/or PE.
DVT: deep vein thrombosis; PE: pulmonary embolism.
Table 3 Calculation of non-inferiority margins based on
14 eligible studies




Point estimate of current
standard of care vs placebo,
‘no treatment’ or ‘less
intensive treatment’
0.18 (0.14−0.25) 0.19 (0.12−0.28)
Reversed point estimate of
current standard of care vs
placebo, ‘no treatment’ or
‘less intensive treatment’
5.56 (4.00−7.14) 5.26 (3.57−8.33)










of 50% of effect
2.50/2.00 2.29/1.89
Threshold for preservation
of 66% of effect
2.00/1.60 1.86/1.54
Threshold for preservation
of 75% of effect
1.75/1.41 1.64/1.37
Threshold for preservation
of 100% of effect*
1.00/1.00 1.00/1.00
*Superiority versus current standard of care.
CI: confidence interval.
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varied between placebo and ‘no treatment’ or some form
of anticoagulant treatment that lacked evidence of effi-
cacy. Despite the lack of evidence of efficacy, it cannot
be excluded that these ‘less intensive’ anticoagulant regi-
mens offered some protection against recurrent VTE,
which would make our estimates of effect and accom-
panying non-inferiority margins relatively conservative.
No statistical heterogeneity was identified when combining
the results of the 14 identified studies. Based on the
consistency of the observed effect in all studies and the
high number of patients in the meta- analysis, the 95% CIs
around the observed summary treatment effect are rela-
tively narrow. With the observed large risk reduction, the
calculated non-inferiority margin to demonstrate mainten-
ance of 50% of the treatment effect, a commonly accepted
approach, is 2.50 on a linear scale, which might be viewed
as unacceptable because it involves clinically important
events.
On a geometric scale, the comparable number for
the non-inferiority margin would be 2.00. From ourcalculations, it is apparent that calculating a summary
relative risk and then applying a geometric scale results
in more stringent non-inferiority margins (Table 3).
Part of this effect is caused by the wider CI around the
summary effect estimate when using risk ratios rather
than odds ratios, as a result of the different underlying
statistical models. The other important choice is using an
arithmetic (linear) or geometric scale. When reasoning
from the event rate in a ‘no treatment’ situation, the logical
choice would be to use a geometric scale (relative reduc-
tion of outcome rates upon relative reduction). However,
when clinically evaluating the allowed excess of outcome
events versus current standard treatment, the starting
point is the observed incidence on current standard treat-
ment and the logical choice would be to use a linear scale.
Recent published studies that evaluated direct oral anti-
coagulants in patients with symptomatic DVT and/or PE
used 1.80, 2.00, 2.75 and 2.85 as non-inferiority margins to
calculate their sample size. For the EINSTEIN DVT and
EINSTEIN PE studies that evaluated the direct Factor Xa
inhibitor rivaroxaban, it was calculated that a total of 88
events were needed for each study to demonstrate non-
inferiority versus standard of care with a margin of 2.0
[24,25]. The observed upper limits of the 95% CIs
around the relative treatment effect were 1.04 in the
EINSTEIN DVT study, 1.68 in the EINSTEIN PE study,
and 1.19 for all patients in the EINSTEIN DVT and
EINSTEIN PE studies, corresponding to a retention of
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linear scale. Using a geometric scale, these values become
97%, 63% and 87%, respectively. In the RE-COVER and
RE-MEDY studies that evaluated the direct thrombin in-
hibitor dabigatran versus current standard treatment in pa-
tients with DVT and/or PE, it was calculated that 46 and
40 events were needed for each of the studies to demon-
strate non-inferiority versus standard of care with a margin
of 2.75 and 2.85, respectively [26,27]. The observed upper
limits of the 95% CIs around the relative treatment effect
were 1.84 in the RE-COVER trial and 2.64 in RE-MEDY
trial, corresponding to retention of treatment effect of 72%
and 45%, respectively, on a linear scale. Using a geometric
scale, these values become 56% and 30%, respectively. For
the AMPLIFY study that evaluated the direct Factor Xa
inhibitor apixaban in patients with DVT and/or PE, it was
calculated that a total of 123 events were needed to dem-
onstrate non-inferiority versus standard of care with a mar-
gin of 1.80 [28]. The observed upper limits of the 95% CIs
around the relative treatment effect were 1.26 in patients
with DVT, 1.61 in patients with PE, and 1.18 for all
patients, corresponding to a retention of treatment effect
of 91%, 79% and 94%, respectively, on a linear scale. Using
a geometric scale, these values become 83%, 65% and 88%,
respectively. In the HOKUSAI-VTE study, evaluating the
direct Factor Xa inhibitor edoxaban in patients with symp-
tomatic DVT and/or PE, a non-inferiority margin of 1.50
has been adopted (clinicaltrials.gov: NCT00986154) [29].
In summary, the available studies allow the calculation
of non-inferiority margins using a statistical approach
that are appropriate for the evaluation of direct oral
anticoagulants in patients with DVT and/or PE. Studies
on direct oral anticoagulants that were conducted or are
ongoing have adopted various margins and differ in the
amount of retention of treatment effect that they have
demonstrated.
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